These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 23861795)

  • 1. An observational study of circulating tumor cells and (18)F-FDG PET uptake in patients with treatment-naive non-small cell lung cancer.
    Nair VS; Keu KV; Luttgen MS; Kolatkar A; Vasanawala M; Kuschner W; Bethel K; Iagaru AH; Hoh C; Shrager JB; Loo BW; Bazhenova L; Nieva J; Gambhir SS; Kuhn P
    PLoS One; 2013; 8(7):e67733. PubMed ID: 23861795
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of circulating tumour cells with early relapse and 18F-fluorodeoxyglucose positron emission tomography uptake in resected non-small-cell lung cancers.
    Bayarri-Lara CI; de Miguel Pérez D; Cueto Ladrón de Guevara A; Rodriguez Fernández A; Puche JL; Sánchez-Palencia Ramos A; Ruiz Zafra J; Giraldo Ospina CF; Delgado-Rodríguez M; Expósito Ruiz M; Moyano Rodriguez MJ; Lorente JA; Serrano MJ
    Eur J Cardiothorac Surg; 2017 Jul; 52(1):55-62. PubMed ID: 28369376
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correlations between circulating tumor cell phenotyping and 18F-fluorodeoxyglucose positron emission tomography uptake in non-small cell lung cancer.
    Bian J; Yan K; Liu N; Xu X
    J Cancer Res Clin Oncol; 2020 Oct; 146(10):2621-2630. PubMed ID: 32661602
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 18F-FDG PET/CT and circulating tumor cells in treatment-naive patients with non-small-cell lung cancer.
    Zhang F; Wu X; Zhu J; Huang Y; Song X; Jiang L
    Eur J Nucl Med Mol Imaging; 2021 Sep; 48(10):3250-3259. PubMed ID: 33630146
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fluid biopsy for circulating tumor cell identification in patients with early-and late-stage non-small cell lung cancer: a glimpse into lung cancer biology.
    Wendel M; Bazhenova L; Boshuizen R; Kolatkar A; Honnatti M; Cho EH; Marrinucci D; Sandhu A; Perricone A; Thistlethwaite P; Bethel K; Nieva J; Heuvel Mv; Kuhn P
    Phys Biol; 2012 Feb; 9(1):016005. PubMed ID: 22307026
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Circulating tumor microemboli diagnostics for patients with non-small-cell lung cancer.
    Carlsson A; Nair VS; Luttgen MS; Keu KV; Horng G; Vasanawala M; Kolatkar A; Jamali M; Iagaru AH; Kuschner W; Loo BW; Shrager JB; Bethel K; Hoh CK; Bazhenova L; Nieva J; Kuhn P; Gambhir SS
    J Thorac Oncol; 2014 Aug; 9(8):1111-9. PubMed ID: 25157764
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Circulating Tumor DNA Reflects Tumor Metabolism Rather Than Tumor Burden in Chemotherapy-Naive Patients with Advanced Non-Small Cell Lung Cancer:
    Morbelli S; Alama A; Ferrarazzo G; Coco S; Genova C; Rijavec E; Bongioanni F; Biello F; Dal Bello MG; Barletta G; Massollo M; Vanni I; Piva R; Nieri A; Bauckneht M; Sambuceti G; Grossi F
    J Nucl Med; 2017 Nov; 58(11):1764-1769. PubMed ID: 28450567
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Primary tumor SUVmax measured on (18)F-FDG PET-CT correlates with histologic grade and pathologic stage in non-small cell lung cancer].
    Zhao SJ; Wu N; Zheng R; Liu Y; Zhang WJ; Liang Y; Zhang H; Li XM
    Zhonghua Zhong Liu Za Zhi; 2013 Oct; 35(10):754-7. PubMed ID: 24378097
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential (18)F-FDG and (18)F-FLT Uptake on Serial PET/CT Imaging Before and During Definitive Chemoradiation for Non-Small Cell Lung Cancer.
    Everitt SJ; Ball DL; Hicks RJ; Callahan J; Plumridge N; Collins M; Herschtal A; Binns D; Kron T; Schneider M; MacManus M
    J Nucl Med; 2014 Jul; 55(7):1069-74. PubMed ID: 24833494
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic value of SUVmax and metabolic tumor volume on 18F-FDG PET/CT in early stage non-small cell lung cancer patients without LN metastasis.
    Yoo IeR; Chung SK; Park HL; Choi WH; Kim YK; Lee KY; Wang YP
    Biomed Mater Eng; 2014; 24(6):3091-103. PubMed ID: 25227018
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multiblock Discriminant Analysis of Integrative
    Lee SH; Kao GD; Feigenberg SJ; Dorsey JF; Frick MA; Jean-Baptiste S; Uche CZ; Cengel KA; Levin WP; Berman AT; Aggarwal C; Fan Y; Xiao Y
    Int J Radiat Oncol Biol Phys; 2021 Aug; 110(5):1451-1465. PubMed ID: 33662459
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Circulating Tumor Cells Enriched by the Depletion of Leukocytes with Bi-Antibodies in Non-Small Cell Lung Cancer: Potential Clinical Application.
    Yin J; Wang Y; Yin H; Chen W; Jin G; Ma H; Dai J; Chen J; Jiang Y; Wang H; Liu Z; Hu Z; Shen H
    PLoS One; 2015; 10(8):e0137076. PubMed ID: 26317979
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fluorodeoxyglucose positron emission tomography and chemotherapy-related tumor marker expression in non-small cell lung cancer.
    Duan XY; Wang W; Wang JS; Shang J; Gao JG; Guo YM
    BMC Cancer; 2013 Nov; 13():546. PubMed ID: 24237755
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Circulating tumor cells as a response monitor in stage IV non-small cell lung cancer.
    Shishido SN; Carlsson A; Nieva J; Bethel K; Hicks JB; Bazhenova L; Kuhn P
    J Transl Med; 2019 Aug; 17(1):294. PubMed ID: 31462312
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Volume-based assessment by (18)F-FDG PET/CT predicts survival in patients with stage III non-small-cell lung cancer.
    Hyun SH; Ahn HK; Kim H; Ahn MJ; Park K; Ahn YC; Kim J; Shim YM; Choi JY
    Eur J Nucl Med Mol Imaging; 2014 Jan; 41(1):50-8. PubMed ID: 23948859
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Timing of fluorodeoxyglucose positron emission tomography maximum standardized uptake value for diagnosis of local recurrence of non-small cell lung cancer after stereotactic body radiation therapy.
    Tan D; Gill S; Loh N
    Cancer Med; 2020 Oct; 9(20):7469-7476. PubMed ID: 32846054
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Circulating tumor cells in patients with advanced urothelial carcinoma of the bladder: Association with tumor stage, lymph node metastases, FDG-PET findings, and survival.
    Abrahamsson J; Aaltonen K; Engilbertsson H; Liedberg F; Patschan O; Rydén L; Sjödahl G; Gudjonsson S
    Urol Oncol; 2017 Oct; 35(10):606.e9-606.e16. PubMed ID: 28676151
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relationship between primary lesion metabolic parameters and clinical stage in lung cancer.
    Sahiner I; Atasever T; Akdemir UO; Ozturk C; Memis L
    Rev Esp Med Nucl Imagen Mol; 2013; 32(6):357-63. PubMed ID: 23747221
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correlation between FDG-PET/CT findings and solid type non-small cell cancer prognostic factors: are there differences between adenocarcinoma and squamous cell carcinoma?
    Ito R; Iwano S; Kishimoto M; Ito S; Kato K; Naganawa S
    Ann Nucl Med; 2015 Dec; 29(10):897-905. PubMed ID: 26342592
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Circulating tumor cells and [18F]fluorodeoxyglucose positron emission tomography/computed tomography for outcome prediction in metastatic breast cancer.
    De Giorgi U; Valero V; Rohren E; Dawood S; Ueno NT; Miller MC; Doyle GV; Jackson S; Andreopoulou E; Handy BC; Reuben JM; Fritsche HA; Macapinlac HA; Hortobagyi GN; Cristofanilli M
    J Clin Oncol; 2009 Jul; 27(20):3303-11. PubMed ID: 19451443
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.